Kelly J. Kennedy
Kelly J. Kennedy's purchase track record
Kelly J. Kennedy has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/14/2026 | VITL | $21K | +36.1% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Vital Farms faces egg pricing pressure, shares trade lower. Vital Farms shares have declined more steeply than the broader market, with recent reports highlighting egg pricing pressure as a key factor. Jefferies noted this cost headwind, contributing to the stock's recent weakness. The company is currently trading near its established support level, reflecting ongoing market caution regarding its cost structure.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Satellogic shares Merlin.01 orbit images as sector faces headwinds. Satellogic and HEO released images of the Merlin.01 satellite in orbit, marking a milestone 18 months after the program began. This progress comes as space-related stocks trade lower due to rising U.S. inflation data and bond yields, which increase borrowing costs for the sector. The stock is currently trading near its 52-week low, reflecting broader market pressure on high-beta space companies despite recent operational updates.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
HNST: Earnings improve but business outlook remains uncertain. A recent Seeking Alpha article notes that The Honest Company posted better-than-expected earnings, showing improvement in revenue and margins. However, the piece also points to ongoing questions about the durability of its business model and growth prospects. The commentary comes as the stock trades near its long‑standing support level of $2.70.
Transaction History
| GDRX | ▲ Buy | Grant | 73,434 | $0 | 6/16/2026 | View on chart |
| VITL | ▲ Buy | Grant | 10,436 | $0 | 6/10/2026 | View on chart |
| SATL | ▲ Buy | Option Exercise | 49,435 | $0 | 5/31/2026 | View on chart |
| VITL | ▲ Buy | Open Market | 2,500 | $21K | 5/14/2026 | View on chart |
| GDRX | ▲ Buy | Option Exercise | 23,149 | — | 12/21/2025 | View on chart |
| VITL | ▲ Buy | Grant | 3,423 | $0 | 6/11/2025 | View on chart |
| GDRX | ▲ Buy | Grant | 57,050 | $0 | 6/3/2025 | View on chart |
| SATL | ▲ Buy | Option Exercise | 131,250 | $0 | 5/31/2025 | View on chart |
| GDRX | ▲ Buy | Option Exercise | 23,150 | $103K | 12/21/2024 | View on chart |
| GDRX | ▲ Buy | Grant | 2,464 | $0 | 7/8/2024 | View on chart |
| VITL | ▲ Buy | Grant | 2,136 | $0 | 6/12/2024 | View on chart |
| GDRX | ▲ Buy | Grant | 28,398 | $0 | 6/6/2024 | View on chart |
| VITL | ▼ Sell | Open Market | 10,971 | $388K | 5/13/2024 | View on chart |
| HNST | ▼ Sell | Open Market | 40,327 | $50K | 10/2/2023 | View on chart |
| HNST | ▼ Sell | Open Market | 6,621 | $9K | 8/21/2023 | View on chart |
| HNST | ▼ Sell | Open Market | 1,260 | $2K | 7/28/2023 | View on chart |
| VITL | ▲ Buy | Grant | 6,086 | $0 | 6/7/2023 | View on chart |
| HNST | ▼ Sell | Open Market | 6,801 | $11K | 5/22/2023 | View on chart |
| HNST | ▼ Sell | Tax Withholding | 1,239 | $2K | 5/1/2023 | View on chart |
| HNST | ▲ Buy | Grant | 382,142 | $0 | 3/21/2023 | View on chart |
| HNST | ▼ Sell | Open Market | 15,904 | $46K | 3/6/2023 | View on chart |
| HNST | ▼ Sell | Open Market | 1,535 | $5K | 1/30/2023 | View on chart |
| HNST | ▼ Sell | Open Market | 3,933 | $11K | 11/21/2022 | View on chart |
| HNST | ▼ Sell | Open Market | 1,227 | $4K | 10/28/2022 | View on chart |
| HNST | ▼ Sell | Open Market | 3,814 | $14K | 8/22/2022 | View on chart |
| HNST | ▼ Sell | Open Market | 1,169 | $4K | 7/28/2022 | View on chart |
| VITL | ▲ Buy | Grant | 8,782 | $0 | 6/8/2022 | View on chart |
| HNST | ▼ Sell | Open Market | 3,694 | $12K | 5/20/2022 | View on chart |
| HNST | ▼ Sell | Open Market | 46,344 | $188K | 5/5/2022 | View on chart |
| HNST | ▼ Sell | Open Market | 1,218 | $5K | 4/27/2022 | View on chart |
| HNST | ▲ Buy | Grant | 175,123 | $0 | 3/24/2022 | View on chart |
| HNST | ▼ Sell | Open Market | 6,047 | $35K | 1/28/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
GoodRx Expands Savings Offering With Companion Family Plan for Pets and People
GoodRx has launched a Companion Family Plan that extends its healthcare savings to pets as well as household members. The company is positioning the new offering as a way to bring prescription and care discounts to the entire family, including animals, broadening the appeal of its platform. Separately, a recent market analysis listed GoodRx among stocks viewed as having mixed momentum. The company is already trading near a well-tested support level, providing some technical context around the announcement.
GoodRx Expands Savings Offering With Companion Family Plan for Pets and People. GoodRx has launched a Companion Family Plan that extends its healthcare savings to pets as well as household members. The company is positioning the new offering as a way to bring prescription and care discounts to the entire family, including animals, broadening the appeal of its platform. Separately, a recent market analysis listed GoodRx among stocks viewed as having mixed momentum. The company is already trading near a well-tested support level, providing some technical context around the announcement.